Diagnostic role of circulating free plasma DNA detection in patients with localized prostate cancer
Diagnostic role of circulating free plasma DNA detection in patients with localized prostate cancer
复制标题
DOI:
10.1309/dbpx1mfnddjbw1fl
复制
发表时间:
2008-05-01
影响因子:
3.5
通讯作者:
Fiorentino, Michelangelo
中科院分区:
文献类型:
--
作者:
Altimari, Annalisa;Grigioni, Antonia D'Errico;Fiorentino, Michelangelo
To analyze the potential diagnostic relevance of free plasma DNA (FPDNA), we enrolled 64 patients with localized prostate cancer (CaP). FPDNA was quantified by real-time polymerase chain reaction assessment of the HTERT gene in blood samples from 64 patients with CaP and 45 healthy males. Methylation of the GSTP I gene was used to confirm the neoplastic origin of FPDNA in selected cases.The mean SD levels of FPDNA were higher in patients with CaP (15.4 +/- 10.9 ng/mL) than in control subjects (5.5 +/- 3.5 ng/mL; P < . 001). By using, the best cutoff value, the sensitivity of the test was 80%, the specificity was 82%, the area under the receiver operating characteristic curve, 0.881. High FPDNA values were significantly associated with pathologic T3 stage (P =.035). Methylation of the GSTP1 gene was found in 4 (25%) of 16 FPDNA samples and 15 (94%) of 16 tissue samples.Quantification of FPDNA discriminates between patients with CaP and healthy subjects and correlates with pathologic tumor stage. FPDNA is a candidate biomarker for early diagnosis and monitoring of CaP.